Insider · CIK 0001531178

Edick Paul R

Reports to the SEC for 10 companies · AMES, IA

sec.gov

Transactions

Companies

Filings

CIK

0001531178

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2025-10-27	VTGNVistagen Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+35.2K sh	—	—	35,200
2024-01-31	XERSXeris Biopharma Holdings, Inc.A Award	Director, See Remarks	AAward	+1.5M sh	—	—	3,788,064
2024-01-31	XERSXeris Biopharma Holdings, Inc. · Stock Appreciation RightA Award	Director, See Remarks	AAward	+500K sh	—	—	500,000
2023-08-09	XERSXeris Biopharma Holdings, Inc.P Purchase	Director, See Remarks	PPurchase	+10K sh	$2.38	+$23.8K	2,288,064
2023-01-31	XERSXeris Biopharma Holdings, Inc.A Award	Director, See Remarks	AAward	+750K sh	—	—	2,278,064
2022-12-13	XERSXeris Biopharma Holdings, Inc.P Purchase	Director, See Remarks	PPurchase	+20K sh	$1.45	+$29K	1,528,064
2022-05-12	XERSXeris Biopharma Holdings, Inc.P Purchase	Director, See Remarks	PPurchase	+100K sh	$1.40	+$140K	1,508,064
2022-01-03	XERSXeris Biopharma Holdings, Inc.A Award	Director, See Remarks	AAward	+600K sh	—	—	1,408,064
2021-11-15	XERSXeris Biopharma Holdings, Inc.P Purchase	Director, See Remarks	PPurchase	+20K sh	$2.28	+$45.7K	33,430
2021-11-11	XERSXeris Biopharma Holdings, Inc.P Purchase	Director, See Remarks	PPurchase	+200K sh	$2.08	+$416K	808,064
2021-10-05	XERSXeris Biopharma Holdings, Inc. · Stock Option (Right to Buy)A Award	Director, See Remarks	AAward	+668K sh	—	—	668,065
2021-10-05	XERSXeris Biopharma Holdings, Inc.A Award	Director, See Remarks	AAward	+13.4K sh	—	—	13,430
2021-10-05	XERSXeris Biopharma Holdings, Inc.A Award	Director, See Remarks	AAward	+197K sh	—	—	197,231
2021-10-05	XERIS PHARMACEUTICALS INCStock Option (Right to Buy)D Disposition to Issuer	Director, Chief Executive Officer	DDisposition to Issuer	−400K sh	—	—	0
2021-10-05	XERIS PHARMACEUTICALS INCStock Option (Right to Buy)D Disposition to Issuer	Director, Chief Executive Officer	DDisposition to Issuer	−200K sh	—	—	0
2021-10-05	XERIS PHARMACEUTICALS INCStock Option (Right to Buy)D Disposition to Issuer	Director, Chief Executive Officer	DDisposition to Issuer	−98.3K sh	—	—	0
2021-10-05	XERIS PHARMACEUTICALS INCStock Option (Right to Buy)D Disposition to Issuer	Director, Chief Executive Officer	DDisposition to Issuer	−69.8K sh	—	—	0
2021-10-05	XERIS PHARMACEUTICALS INCStock Option (Right to Buy)D Disposition to Issuer	Director, Chief Executive Officer	DDisposition to Issuer	−668K sh	—	—	0
2021-10-05	XERIS PHARMACEUTICALS INCD Disposition to Issuer	Director, Chief Executive Officer	DDisposition to Issuer	−13.4K sh	—	—	0
2021-10-05	XERIS PHARMACEUTICALS INCD Disposition to Issuer	Director, Chief Executive Officer	DDisposition to Issuer	−411K sh	—	—	0
2021-10-05	XERIS PHARMACEUTICALS INCD Disposition to Issuer	Director, Chief Executive Officer	DDisposition to Issuer	−197K sh	—	—	410,833
2021-10-05	XERSXeris Biopharma Holdings, Inc.A Award	Director, See Remarks	AAward	+411K sh	—	—	608,064
2021-10-05	XERSXeris Biopharma Holdings, Inc. · Stock Option (Right to Buy)A Award	Director, See Remarks	AAward	+400K sh	—	—	400,000
2021-10-05	XERSXeris Biopharma Holdings, Inc. · Stock Option (Right to Buy)A Award	Director, See Remarks	AAward	+200K sh	—	—	200,000
2021-10-05	XERSXeris Biopharma Holdings, Inc. · Stock Option (Right to Buy)A Award	Director, See Remarks	AAward	+98.3K sh	—	—	98,252
2021-10-05	XERSXeris Biopharma Holdings, Inc. · Stock Option (Right to Buy)A Award	Director, See Remarks	AAward	+69.8K sh	—	—	69,822
2021-01-29	XERIS PHARMACEUTICALS INCStock Option (Right to Buy)A Award	Director, Chief Executive Officer	AAward	+400K sh	—	—	400,000
2021-01-29	XERIS PHARMACEUTICALS INCA Award	Director, Chief Executive Officer	AAward	+225K sh	—	—	636,134
2020-12-09	XERIS PHARMACEUTICALS INCP Purchase	Director, Chief Executive Officer	PPurchase	+10K sh	$4.06	+$40.6K	411,134
2020-06-05	MISTMilestone Pharmaceuticals Inc. · Stock Option (right to buy)A Award	Director	AAward	+15K sh	—	—	15,000
2020-05-08	XERIS PHARMACEUTICALS INCP Purchase	Director, Chief Executive Officer	PPurchase	+33K sh	$3.00	+$99K	401,134
2020-02-14	XERIS PHARMACEUTICALS INCP Purchase	Director, Chief Executive Officer	PPurchase	+20K sh	$4.15	+$83K	183,134
2020-01-31	XERIS PHARMACEUTICALS INCF Tax Payment	Director, Chief Executive Officer	FTax Payment	−9,801 sh	$6.37	−$62.4K	163,134
2020-01-31	XERIS PHARMACEUTICALS INCA Award	Director, Chief Executive Officer	AAward	+185K sh	—	—	368,134
2019-11-25	XERIS PHARMACEUTICALS INCP Purchase	Director, Chief Executive Officer	PPurchase	+17.9K sh	$8.55	+$153K	172,935
2019-05-24	ITRMIterum Therapeutics plc · Restricted Stock UnitsM Exercise/Conversion	Director	MExercise/Conversion	−6,154 sh	—	—	0
2019-05-24	ITRMIterum Therapeutics plcM Exercise/Conversion	Director	MExercise/Conversion	+6,154 sh	—	—	31,390
2019-03-11	XERIS PHARMACEUTICALS INCP Purchase	Director, Chief Executive Officer	PPurchase	+30K sh	$9.12	+$274K	155,000
2019-01-31	XERIS PHARMACEUTICALS INCStock Option (right to buy)A Award	Director, Chief Executive Officer	AAward	+200K sh	—	—	200,000
2019-01-31	XERIS PHARMACEUTICALS INCA Award	Director, Chief Executive Officer	AAward	+125K sh	—	—	125,000
2018-08-23	ITRMIterum Therapeutics plcP Purchase	Director	PPurchase	+500 sh	$10.44	+$5,218.7	25,236
2018-06-25	XERIS PHARMACEUTICALS INCC Conversion	Director, Chief Executive Officer	CConversion	+13.4K sh	—	—	13,430
2018-06-25	XERIS PHARMACEUTICALS INCSeries C Preferred StockC Conversion	Director, Chief Executive Officer	CConversion	−23.9K sh	—	—	0
2018-06-08	PDL BIOPHARMA, INC.A Award	Director	AAward	+54.3K sh	$2.76	+$150K	214,563
2018-05-30	ITRMIterum Therapeutics plcC Conversion	Director	CConversion	+4,050 sh	—	—	23,145
2018-05-30	ITRMIterum Therapeutics plc · Series A Preferred SharesC Conversion	Director	CConversion	−15.9K sh	—	—	0
2018-05-30	ITRMIterum Therapeutics plc · Series B-1 Preferred SharesC Conversion	Director	CConversion	−4,050 sh	—	—	0
2018-05-30	ITRMIterum Therapeutics plc · Series B-2 Preferred SharesC Conversion	Director	CConversion	−1,591 sh	—	—	0
2018-05-30	ITRMIterum Therapeutics plcC Conversion	Director	CConversion	+15.9K sh	—	—	19,095
2018-05-30	ITRMIterum Therapeutics plcC Conversion	Director	CConversion	+1,591 sh	—	—	24,736

Recent filings

Accepted (ET)
Nov 44
Edick Paul R0001531178-25-000007
SEC(opens sec.gov)
Jan 314
Edick Paul R0001867096-24-000014
SEC(opens sec.gov)
Aug 94
Edick Paul R0001867096-23-000117
SEC(opens sec.gov)
Feb 14
Edick Paul R0001867096-23-000023
SEC(opens sec.gov)
Dec 144
Edick Paul R0001867096-22-000131
SEC(opens sec.gov)
May 134
Edick Paul R0001867096-22-000067
SEC(opens sec.gov)
Jan 54
Edick Paul R0001867096-22-000007
SEC(opens sec.gov)
Nov 164
Edick Paul R0001867096-21-000080
SEC(opens sec.gov)
Nov 124
Edick Paul R0001867096-21-000076
SEC(opens sec.gov)
Oct 54
Edick Paul R0000899243-21-039254
SEC(opens sec.gov)
Oct 54
Edick Paul R0000899243-21-039335
SEC(opens sec.gov)

Companies

Address

C/O NEWLINK GENETICS CORPORATION 2503 SOUTH LOOP DR., SUITE 5100

AMES, IA, 50010